



Atty. Dkt. No. 022726-0201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MADISON et al.

Title: TARGETED THERAPEUTIC OR
DIAGNOSTIC AGENTS AND
METHODS OF MAKING AND
USING SAME

Appl. No.: 09/091,578

Filing Date: 10/6/1998

Examiner: Schwadron, Ronald B.

Art Unit: 1644

<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p><u>Line Gauthier</u> (Printed Name)</p> <p><u>Line Gauthier</u> (Signature)</p> <p><u>June 2, 2004</u> (Date of Deposit)</p>
--

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

06/08/2004 LWONDIM1 00000040 09091578

01 FC:1806

180.00 OP

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of a supplemental information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.


Date May 27, 2004

Richard J. Warburg
FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6700
Facsimile: (858) 792-6773

Respectfully submitted,

By Richard San Pietro

Richard San Pietro
Attorney for Applicant
Registration No. 45,071



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Date Submitted: 6/2/2004

(use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number	09/091,578
Filing Date	10/6/1998
First Named Inventor	Edwin L. Madison
Group Art Unit	1644
Examiner Name	Schwadron, Ronald B.
Attorney Docket Number	022726-0201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	EPO	0 271 227 B1		The General Hospital Corp.	09.06.93		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A2	Aki et al., "Interferon- γ induces different subunit organizations and functional diversity of proteasomes," <i>J. Biochem.</i> 115:257-269 (1994)	
	A3	Backstrom et al., "Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli," <i>gene</i> , 165:163-171 (1995)	
	A4	Barbas III et al., "High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site," <i>Proc. Natl. Acad. Sci. USA</i> 90:10003-1007 (November 1993)	
	A5	Barbars, Carlos F., "Recent advances in phage display," <i>Current Opinion in Biotech.</i> 4:526-530 (1993)	
	A6	Bass et al., "A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor," <i>Proc. Natl. Acad. Sci. USA</i> 88:4498-4502 (May 1991)	
	A7	Bassel-Duby et al., "Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor," <i>Journ. Of Biol. Chem.</i> 267(4):9668-9677 (1992)	


DLMR254013.1

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: _____

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	09/091,578
Filing Date	10/6/1998
First Named Inventor	Edwin L. Madison
Group Art Unit	1644
Examiner Name	Schwadron, Ronald B.
Attorney Docket Number	022726-0201

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A8	Bei et al., "Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein," <i>Journ. Immunol. Methods</i> 186:245-255 (1995)	
	A9	Bode et al., "Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation," <i>Circulation</i> 84(2):805-813 (August 1991)	
	A10	Browne et al., "A tissue-type plasminogen activator mutant with prolonged clearance in vivo," <i>The Journal of Biol. Chem.</i> 283(4):1599-1602 (1988)	
	A11	Charo et al., "The vitronectin receptor $\alpha_5\beta_3$ binds fibronectin and acts in concert with $\alpha_5\beta_1$ in promoting cellular attachment and spreading on fibronectin," <i>The Journal of Cell Biology</i> 111(6,1):2795-2800 (1990)	
	A12	Gheon et al., "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <i>Proc. Natl. Acad. Sci. USA</i> 91:989-993 (February 1994)	
	A13	Coux et al., "Structure and functions of the 20S and 26S proteasomes," <i>Annu. Rev. Biochem.</i> 65:801-47 (1996)	
	A14	Cunningham et al., "Engineering human prolactin to bind to the human growth hormone receptor," <i>Science</i> 247:1461-1465 (1990)	
	A15	Dahlmann et al., "Purification and characterization of a multicatalytic high-molecular-mass proteinase from rat skeletal muscle," <i>Biochem.</i> 228:161-170 (1985)	
	A16	Dahlmann et al., "Studies on the activation by ATP of the 26S proteasome complex from rat skeletal muscle," <i>Biochem. J.</i> 309:195-202 (1995)	
	A17	Dahlmann et al., "The multicatalytic proteinase: a high- M_r endopeptidase," <i>BJ Letters</i> 255:750-1 (1988)	
	A18	De Lorimier et al., "NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus," <i>Biochemistry</i> 33:2055-2062 (1994)	


DI MR254013.1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: _____

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	09/091,578
Filing Date	10/6/1998
First Named Inventor	Edwin L. Madison
Group Art Unit	1644
Examiner Name	Schwadron, Ronald B.
Attorney Docket Number	022726-0201

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A19	Dewerchin et al., "Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo," <i>Blood</i> 78(4):1005-1018 (August 15)	
	A20	Duarte et al., "Multiepitope of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop," <i>AIDS Research and Human Retroviruses</i> 10(3):235-243 (1994)	
	A21	Gething et al., "Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain," <i>EMBO J.</i> 7(9):2731-40 (September 1988)	
	A22	Hashino et al., "Engineering of artificial cell adhesion proteins by grafting the arg-gly-asp cell adhesive signal to a calpastatin segment," <i>J. Biochem.</i> 112:547-551 (1992)	
	A23	Hearst et al., "GRAFTER: a computational aid for the design of novel proteins," <i>Protein Engin.</i> 7(12):1411-1421 (1994)	
	A24	Janin et al., "The structure of protein-protein recognition sites," <i>The Journal of Biological Chemistry</i> 265(27):16027-16030 (1990)	
	A25	Johannessen et al., "Fibrin affinity and clearance of t-PA deletion and substitution analogues," <i>Throm. Haemost.</i> 63:54-59 (1990)	
	A26	Kagitani et al., "Expression in E. Coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity," <i>FEBS</i> 189(1):145-149 (September 1985)	
	A27	Kalyan et al., "Structure-function analysis with tissue-type plasminogen activator," <i>The Journal of Biological Chemistry</i> 263(8):3971-3978 (March 15, 1988)	
	A28	Kohda et al., "Tertiary structure of mouse epidermal growth factor determined by two-dimensional H NMR," <i>J. Biochem.</i> 103:741-743 (1988)	
	A29	Kunkel et al., "Rapid and efficient site-specific mutagenesis without phenotypic selection," <i>Proc. Natl. Acad. Sci. USA</i> 82:488-492 (January 1985)	
	A30	Larsen et al., "Variants of human tissue-type plasminogen activator," <i>The Journal of Biological Chemistry</i> 263(2):1023-1029 (January 15, 1988)	


DLMR254013.1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: _____

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	09/091,578
Filing Date	10/6/1998
First Named Inventor	Edwin L. Madison
Group Art Unit	1644
Examiner Name	Schwadron, Ronald B.
Attorney Docket Number	022726-0201

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A31	Madison et al., "Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1," <i>Proc. Natl. Acad. Sci. USA</i> 87:3530-3533 (May 1990)	
	A32	Madison et al., "Probing Structure—Function relationships of tissue-type plasminogen activator by oligonucleotide-mediated site-specific mutagenesis," <i>Methods in Enzymology</i> 223:249-271 (1993)	
	A33	Madison et al., "Restoration of serine protease-inhibitor interaction by protein engineering," <i>The Journal of Biological Chemistry</i> 265(35):21423-21426 (December 15, 1990)	
	A34	Madison et al., "Serpine-resistant mutants of human tissue-type plasminogen activator," <i>Nature</i> 339:721-724 (June 29, 1989)	
	A35	Maeda et al., "A novel cell adhesive protein engineered by insertion of the arg-gly-asp-ser tetrapeptide," <i>The Journal of Biological Chemistry</i> 264(26):15165-15168 (September 15, 1989)	
	A36	Mahmoud et al., "Fibrinolysis in insulin dependent diabetic patients with or without nephropathy," <i>Fibrinolysis</i> 6:105-109 (1992)	
	A37	Mason et al., "Phosphorylation of proteasomes in mammalian cells – identification of two phosphorylated subunits and the effect of phosphorylation on activity," <i>Eur. J. Biochem.</i> 238:453-462 (1996)	
	A38	Paomi et al., "Making tissue-type plasminogen activator more fibrin specific," <i>Protein Engin.</i> 6:529-534 (1993)	
	A39	Pytela et al., "Arginine-glycine-aspartic acid adhesion receptors," <i>Methods in Enzymology</i> 144:475-489 (1987)	
	A40	Scott et al., "Searching for peptide ligands with an epitope library," <i>Science</i> 249:386-390 (1990)	
	A41	Shin et al., "Chimeric antibody: potential applications for drug delivery and immunotherapy," <i>Biotherapy</i> 3:43-53 (1991)	
	A42	Shin et al., "Functional properties of antibody insulin-like growth factor fusion proteins," <i>The Journal of Biological Chemistry</i> 269(7):4979-4985 (1994)	


DLMR254013.1

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: _____ (use as many sheets as necessary)		Complete if Known	
		Application Number	09/091,578
		Filing Date	10/6/1998
		First Named Inventor	Edwin L. Madison
		Group Art Unit	1644
		Examiner Name	Schwadron, Ronald B.
Sheet 5 of 6		Attorney Docket Number	022726-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A43	Smith et al., "A mechanism for divalent cation regulation of β_3 -integrins," <i>The Journal of Biological Chemistry</i> 269(2):960-967 (January 14, 1994)	
	A44	Smith et al., "Building synthetic antibodies as adhesive ligands for integrins," <i>The Journal of Biological Chemistry</i> 269(52):32788-32795 (December 30, 1994)	
	A45	Smith et al., "Interaction of integrins $\alpha_v\beta_3$ and glycoprotein IIb-IIIa with fibrinogen," <i>The Journal of Biological Chemistry</i> 265(21):12267-12271 (July 25, 1990)	
	A46	Smith et al., "Purification and functional characterization of integrin $\alpha_v\beta_5$," <i>The Journal of Biological Chemistry</i> 265(19):11008-11013 (July 5, 1990)	
	A47	Smith et al., "The arg-gly-asp binding domain of the vitronectin receptor," <i>The Journal of Biological Chemistry</i> 263(35):18726-18731 (December 15, 1988)	
	A48	Smith et al., "Purification and functional characterization of integrin $\alpha_v\beta_5$," <i>The Journal of Biological Chemistry</i> 265(19):11008-11013 (July 5, 1990)	
	A49	Swenson et al., "A platelet targeted thrombolytic agent: covalent modification with a platelet avid peptide," Dept. of Biochemistry, School of Medicine, USC, Los Angeles, CA (Abstract)	
	A50	Tanaka et al., "The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon- γ -inducible proteasome activator PA28," <i>Immunol. Review</i> 163:161-176 (1998)	
	A51	Thomas et al., "Potent interleukin 3 receptor agonist with selectivity enhanced hematopoietic activity relative to recombinant human interleukin 3," <i>Proc. Natl. Acad. Sci. USA</i> 92:3779-3783 (April 1995)	
	A52	Van Zonneveld et al., "Autonomous functions of structural domains on human tissue-type plasminogen activator," <i>Proc. Natl. Acad. Sci. USA</i> 83:4670-4674 (July 1986)	
	A53	Verheijen et al., "Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin," <i>EMBO Journal</i> 5(13):3525-3530 (1986)	
	A54	Yamada et al., "Structure of a conformationally constrained arg-gly-asp sequence inserted into human lysozyme," <i>The Journal of Biological Chemistry</i> 270(11):5687-5690 (1995)	


DLMR254013.1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	09/091,578
Date Submitted: _____		Filing Date	10/6/1998
(use as many sheets as necessary)		First Named Inventor	Edwin L. Madison
Sheet 6 of 6		Group Art Unit	1644
		Examiner Name	Schwadron, Ronald B.
		Attorney Docket Number	022726-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A55	Zoller et al., "Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template," <i>DNA</i> 3(6):479-488 (1984)	

DI MR254013.1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.